Amgen Sues Pfizer, Hospira As Neulasta Patent Feud Widens
Pfizer Inc. and Hospira Inc. infringed an Amgen Inc. patent when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patent expired, the biologic...To view the full article, register now.
Already a subscriber? Click here to view full article